 |
Trials |
A Safety and Efficacy Study of Adding Low Dose Pegylated IFN-alpha 2B to Standard Dose Dasatinib in Patients With Newly Diagnosed Chronic Phase Myeloid LeukemiaCancer type: Leukemia Phase: I/II Principal Investigator: Gjertsen Bjørn Tore Country: NO Keywords: Norway, Bergen Status: Inclusion completed Link to Clinicaltrials.gov: http://clinicaltrials.gov/ct2/show/NCT01725204 |